Topic: Drug Discovery

Hugh Rosen: A physician-scientist’s guide to developing medicines

More than 90% of drugs fail to make it from the lab bench to approval. How, then, has a physician-scientist like Hugh Rosen found so much success in developing medicines? Rosen, who’s the chair of the Molecular and Cellular Biology Department and the Pearson Family Chair at Scripps Research, co-invented the drugs ozanimod (approved for multiple sclerosis and ulcerative colitis) and navacaprant (in Phase 3 trials for major depressive disorder). In this episode of Science Changing Life, listen in as Rosen unveils the success stories behind these groundbreaking treatments—shedding light on the challenges and triumphs shaping modern medicine.

From bench to bedside

An engine for new medicines: A century of science changing life

Calibr, a nonprofit research institute founded by Scripps Research President and CEO Pete Schultz, joined Scripps Research in 2018 as its drug discovery division. As a world-class nonprofit “bench to bedside” drug discovery engine, Calibr delivers groundbreaking solutions to unmet medical needs by uniting the creativity of fundamental discovery with highly focused R&D capabilities and expertise.

Of music and medicine

Understanding biological factories to fuel drug discovery

Every organism depends on its ability to make cellular proteins from the core set of genetic blueprints—a process carried out in the cell by ancient biological factories. However, when this building process goes awry, various types of disease can take hold. In this opening lecture of the sixth season, Scripps Research professor and regular Front Row host Jamie Williamson unveiled his lab’s unprecedented exploration of these protein-building machines and the secrets they hold in maintaining cellular health. His cutting-edge research is evolving our view of molecular engineering and uncovering new drug targets for bacterial infections and cancer.

Travis Young: Finding a cure for cancer with novel immunotherapies

Dr. Travis Young is the Vice President of Biologics at Calibr, the drug discovery and development division of Scripps Research. Travis and the team have created a new type of immunotherapy called "switchable" chimeric antigen receptor (CAR) T-cell therapy, which is already delivering precise and powerful therapies to patients with the most difficult to treat cancers. Listen as we talk about reengineering an individual’s immune T cells, promising clinical trials in leukemia and lymphoma patients, and using similar approaches to treat autoimmune diseases.

Chemistry’s impact today